Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
BörsenkürzelPLUR
Name des UnternehmensPluri Inc
IPO-datumDec 10, 2007
CEOMr. Yaky Yanay
Anzahl der mitarbeiter106
WertpapierartOrdinary Share
GeschäftsjahresendeDec 10
AddresseMatam Advanced Technology Park
StadtHAIFA
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl3508409
Telefon972747108600
Websitehttps://pluri-biotech.com/
BörsenkürzelPLUR
IPO-datumDec 10, 2007
CEOMr. Yaky Yanay
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten